Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many of them are aging in good health. However, others present symptoms of cognitive decline. HIV can reach the brain and establish a reservoir there. Yet, it is still unknown what this reservoir is like, which cells are affected, and which comorbidities are typical of aging or are associated with the virus. Read More
Researchers from Model Medicines Inc. have presented preclinical efficacy data for MDL-001, a first-in-class, oral non-nucleoside inhibitor that targets an allosteric site in the Thumb-1 domain of the viral polymerase. Read More
Frontier Biotechnologies Inc. has entered into an exclusive licensing agreement with GSK plc whereby GSK will obtain exclusive worldwide rights to develop, manufacture and commercialize two of Frontier’s small interfering RNA (siRNA) pipeline products. Read More
Porosome Therapeutics Inc. has announced the development of novel first-in-class porosome-targeting small molecules and blood-brain barrier-traversing peptide drugs developed using the company’s Porosome.AI platform to treat various secretory disorders, such as Alzheimer’s disease and type 2 diabetes. Read More
The farnesoid X receptor (FXR) is a nuclear receptor that plays a central role in bile acid regulation, intestinal barrier integrity, immune modulation and microbiome balance, all key factors involved in the development of inflammatory bowel disease (IBD). Researchers from Gilead Sciences Inc. reported the effects of GS-8670, an FXR agonist, in models of colitis. Read More
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache disorders. Read More
Researchers from Spyre Therapeutics Inc. reported on the therapeutic efficacy of combining anti-TL1A and anti-IL-23 antibodies in preclinical models of colitis. Read More
Shanghai Meiyue Biotech Development Co. Ltd. has patented heterocyclic derivatives acting as KIT (c-KIT) inhibitors. They are reported to be useful for the treatment of autoimmune, metabolic disease, cancer, diabetes, fibrosis, urticaria, inflammatory and respiratory disorders, among others. Read More
Waverley Pharma Inc. has discovered substituted (3-hydroquinazolin-4-one) derivatives acting as poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors and thus potentially useful for the treatment of cancer. Read More
A recent study assessed the applicability of McERV-pseudotyped lentiviral vector particles (McERV-PTLVs) to target cancer cells of glial or neuronal origin. Read More
